Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Case study of targeted therapy on human Non-small cell lung cancer

PROVIDER: PRJNA1174043 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31023585_1.fastq.gz	Fastqsanger.gz
	SRR31023585_2.fastq.gz	Fastqsanger.gz
	SRR31023586_1.fastq.gz	Fastqsanger.gz
	SRR31023586_2.fastq.gz	Fastqsanger.gz
	SRR31023587_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Proteogenomic characterization analysis of human large cell lung cancer

Project description:Current clinical therapy of non-small cell lung cancer depends on histo-pathological classification. This approach poorly predicts clinical outcome for individual patients. Proteogenomic characterization analysis holds promise to improve clinical stratification, thus paving the way for individualized therapy. We investigated proteogenomic characterization and performed comprehensive integrative genomic analysis of human large cell lung cancer. Here we analyzed proteomes of 29 paired normal lung tissues and large cell lung cancer, identified significantly deregulated proteins associated with large cell lung cancer.

2019-01-16 | PXD012393 |

24h-response to bevacizumab erlortinib in non-small cell lung cancer from blood-based exon array profiling

Project description:The mechanisms of action of the combined targeted therapy bevacizumab erlotinib in late stage non-squamous non-small cell lung cancer was investigated by means of whole genome exon arrays. mRNA from peripherial blood was extracted at baseline and 24h after initiation of the therapy and hybridized on Affymetrix Human Exon 1.0 ST Arrays

2016-12-31 | GSE61676 | GEO

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC (scRNA-Seq)

Project description:Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.

2024-02-29 | GSE260499 | GEO

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in NSCLC

2024-02-20 | GSE255958 | GEO

Homo sapiens

Project description:Non Small Cell Lung Cancer

| PRJNA90997 | ENA

Exon array analysis of the response to bevacizumab/erlotinib in advanced non-small cell lung cancer

Project description:In the current study, we used exon arrays and clinical samples from a previous trial (SAKK 19/05) to investigate the expression variations at the exon-level of 3 genes potentially playing a key role in modulating treatment response (EGFR, KRAS, VEGFA). Exon-level biomarkers for the response to targeted therapy bevacizumab/erlotinib were identified in patients with metastatic non-small cell lung cancer Multicenter, prospective, open-label, single-arm, phase II trial.

2013-07-30 | E-GEOD-37138 | biostudies-arrayexpress

Human, bronchoalveolar lavage, extracellular vesicles

Project description:The aim of the project was to explore large extracellular vesicles capacity to seperate non lung cancer from lung cancer cases. A case control study of patients suspected for lung cancer (12 non lung cancer and 12 lung cancers). The raw files are labeled according to clinical status. Small and large extracellular vesicles were isolated by differential centrifugation. The proteome of full BAL, vesicle depleted BAL, small and large extracellular vesicles were characterized by LC-MS. Small extracellular vesicles were further analyzed by nanoparticle tracking analysis, Transmission electron microscopy and western blots.

2020-12-15 | PXD021988 | Pride

Therapy-induced APOBEC3A drives evolution of resistance to targeted therapies in non-small cell lung cancer

Project description:Therapy-induced APOBEC3A drives evolution of resistance to targeted therapies in non-small cell lung cancer

| PRJNA954124 | ENA

Therapy-induced APOBEC3A drives evolution of resistance to targeted therapies in non-small cell lung cancer

Project description:Therapy-induced APOBEC3A drives evolution of resistance to targeted therapies in non-small cell lung cancer

| PRJNA954125 | ENA

Expression data from Human non-small cell lung cancer

Project description:Expression data from Human non-small cell lung cancer

| PRJNA608646 | ENA